273 related articles for article (PubMed ID: 31774808)
21. Arenavirus Therapy in Combination with Checkpoint Blockade as an Effective Way for Better Tumour Clearance.
Bhat H; Ali M; Hamdan TA
Cell Physiol Biochem; 2021 Nov; 55(6):726-738. PubMed ID: 34816678
[TBL] [Abstract][Full Text] [Related]
22. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
23. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
[TBL] [Abstract][Full Text] [Related]
24. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.
Kanaya N; Kitamura Y; Lopez Vazquez M; Franco A; Chen KS; van Schaik TA; Farzani TA; Borges P; Ichinose T; Seddiq W; Kuroda S; Boland G; Jahan N; Fisher D; Wakimoto H; Shah K
Sci Transl Med; 2023 May; 15(698):eade8732. PubMed ID: 37256936
[TBL] [Abstract][Full Text] [Related]
25. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.
Alekseenko I; Kuzmich A; Kondratyeva L; Kondratieva S; Pleshkan V; Sverdlov E
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502287
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S
Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic viral therapy: a review and promising future directions.
Reddy R; Yan SC; Hasanpour Segherlou Z; Hosseini-Siyanaki MR; Poe J; Perez-Vega C; Chiocca EA; Lucke-Wold B
J Neurosurg; 2024 Feb; 140(2):319-327. PubMed ID: 37877961
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.
Martin NT; Bell JC
Mol Ther; 2018 Jun; 26(6):1414-1422. PubMed ID: 29703699
[TBL] [Abstract][Full Text] [Related]
29. The use of oncolytic virotherapy in the neoadjuvant setting.
Thomas RJ; Bartee E
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414592
[TBL] [Abstract][Full Text] [Related]
30. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.
Ji Q; Wu Y; Albers A; Fang M; Qian X
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145559
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
32. Talimogene laherparepvec monotherapy for head and neck melanoma patients.
Franke V; Stahlie EHA; Klop WMC; Zuur CL; Berger DMS; van der Hiel B; van de Wiel BA; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Melanoma Res; 2023 Feb; 33(1):66-70. PubMed ID: 36454284
[TBL] [Abstract][Full Text] [Related]
33. Fighting Cancer with Mathematics and Viruses.
Santiago DN; Heidbuechel JPW; Kandell WM; Walker R; Djeu J; Engeland CE; Abate-Daga D; Enderling H
Viruses; 2017 Aug; 9(9):. PubMed ID: 28832539
[TBL] [Abstract][Full Text] [Related]
34. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells.
Tijtgat J; De Munck J; Dufait I; Schwarze JK; Van Riet I; Franceschini L; Breckpot K; Aerts JL; Neyns B; Tuyaerts S
Front Immunol; 2021; 12():733506. PubMed ID: 34777344
[TBL] [Abstract][Full Text] [Related]
35. On the treatment of melanoma: A mathematical model of oncolytic virotherapy.
Ramaj T; Zou X
Math Biosci; 2023 Nov; 365():109073. PubMed ID: 37660975
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.
Soliman H; Hogue D; Han H; Mooney B; Costa R; Lee MC; Niell B; Williams A; Chau A; Falcon S; Soyano A; Armaghani A; Khakpour N; Weinfurtner RJ; Hoover S; Kiluk J; Laronga C; Rosa M; Khong H; Czerniecki B
Nat Med; 2023 Feb; 29(2):450-457. PubMed ID: 36759673
[TBL] [Abstract][Full Text] [Related]
37. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Nguyen VP; Campbell KM; Nowicki TS; Elumalai N; Medina E; Baselga-Carretero I; DiNome ML; Chang HR; Oseguera DK; Ribas A; Glaspy JA
Cancer Res Commun; 2023 Aug; 3(8):1628-1637. PubMed ID: 37621406
[TBL] [Abstract][Full Text] [Related]
38. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic virus preclinical toxicology studies.
Rasa A; Alberts P
J Appl Toxicol; 2023 May; 43(5):620-648. PubMed ID: 36299168
[TBL] [Abstract][Full Text] [Related]
40. Local anesthetics and immunotherapy: a novel combination to fight cancer.
Bezu L; Kepp O; Kroemer G
Semin Immunopathol; 2023 Mar; 45(2):265-272. PubMed ID: 36044068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
